Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07022275 · ClinicalTrials.gov registry record · NA
Safety Evaluation of THC-Free Hemp Protein Isolate
A NA study of Tolerability of Hemp Protein, sponsored by National University of Natural Medicine.
- Active
- Registry status
- NA
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT07022275 is a NA study of Tolerability of Hemp Protein that is active but no longer recruiting, run by National University of Natural Medicine. The registered enrollment target is 32 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07022275, a NA study of Tolerability of Hemp Protein, is active but no longer recruiting, sponsored by National University of Natural Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate the safety and tolerability of a THC-free hemp protein supplement in healthy adult volunteers aged 18-65 years who do not use cannabis or hemp-derived products. The main questions this study aims to answer are: Does twice-daily consumption of 20 grams of Agoge Hemp Protein Powder for 30 days result in detectable levels of THC-COOH, the primary metabolite of THC, in urine samples? Is the supplement well tolerated, and does it affect common clinical safety markers (e.g., liver and kidney function, inflammatory markers)? This is a single-arm study with no comparison group. All participants will: * Consume 20 grams of the hemp protein supplement twice daily for 30 days * Provide blood and urine samples at baseline and Day 30 * Complete weekly surveys assessing adherence, tolerability, and adverse events
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Hemp protein powder
Study Locations (1)
Oregon
- Helfgott Research Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-03-15 |
| Est. Completion | 2025-09-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07022275
The ClinicalTrials.gov registry entry for NCT07022275 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National University of Natural Medicine, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tolerability of Hemp Protein appearing as the primary indexed condition, and to 1 intervention - of which Hemp protein powder is the first listed.
NCT07022275 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT07022275 about?
NCT07022275 is a clinical study titled "Safety Evaluation of THC-Free Hemp Protein Isolate". The goal of this clinical trial is to evaluate the safety and tolerability of a THC-free hemp protein supplement in healthy adult volunteers aged 18-65 years who do not use cannabis or hemp-derived products. The main questions this study aims to answer are: Does twice-daily consumption of 20 grams ...
What is the current status of trial NCT07022275?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2025-03-15. Estimated completion is 2025-09-25.
What conditions does trial NCT07022275 study?
This clinical trial studies the following conditions: Tolerability of Hemp Protein.
What interventions are being tested in trial NCT07022275?
The interventions under investigation include: Hemp protein powder (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07022275?
This trial is sponsored by National University of Natural Medicine, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07022275 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.